By 
Reuters
Pfizer to exit GSK’s consumer health arm after spin-off
LONDON (Reuters) -Pfizer plans to exit its 32% stake in Haleon, its consumer health joint venture with British drugmaker GSK, after the business is spun off as an independent listed company in July, GSK said on Wednesday. Pfizer previously signalled it would seek to sell its shareholding in Haleon, which is home to Sensodyne toothpaste and Advil painkillers, but GSK said in February that the U.S. drugmaker would retain its stake. GSK said on Wednesday that Pfizer would exit its investment in a “disciplined manner”.
Comments